Eosinophils are innate immune leukocytes recruited in large numbers to sites of allergic inflammation and parasitic infections. Recent studies show additional pleiotropic effects of recruited eosinophils impacting immunomodulation, tissue homeostasis and repair. Pathologic conditions accompanied by blood eosinophilia are quite frequent in medical practice and may raise serious differential diagnosis problems in severe cases, that require a multidisciplinary approach. Hypereosinophilia may be reactive to other diseases or primary, representing hypereosinophilic syndromes, that are diagnosed based on clinical and laboratory criteria, according to actual international guidelines. The etiopathogenic diagnosis is difficult and delayed in many cases and clinical evolution may be severe, with multiorgan involvement and poor prognosis. Some cases remain idiopathic, despite exhaustive investigation. This paper aims to review the most recent data in the literature referring to the role of eosinophils in human pathology, diagnostic criteria and treatment strategies of hypereosinophilic syndromes, actual classification and to draw some useful recommendations in clinical practice.
1. MOQBEL R, LACY P, ADAMKO DJ, ODEMUYIWA SO. Biology of Eosinophils. In Middleton’s Allergy Principles and Practice, Seventh Edition. Cap 18, p. 295-310.
2. LACY P, MOQBEL R. Immune effector functions of eosinophils in allergic airway inflammation. Curr Opin Allergy Clin Immunol 2001; 1:79-84.
3. VALENT P, KLION AD, ROSENWASSER LJ, et al. ICON (International Consensus ON): Eosinophilic Disorders. Consensus document. WAO Journal 2012; 5:174-181.
4. GOTLIB J. World Health Organization – defined eosinophilic disorders: 2014 update on diagnosis, risk stratification and management. American Journal of Hematology 2014; 89(3):326-37.
5. GLEICH GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-63.
6. HOGAN SP, ROSENBERG HF, MOQBEL R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38:709-50.
7. WOERLY G, ROGER N, LOISEAU S, et al. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gama: inhibition by immunoglobulin complexes. J Exp Med 1999; 190:487-495.
8. PARDANANI A, PATNAIK MM, TEFFERI A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 2006; 133:468-92.
9. GOTLIB J, COOLS J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010.
10. SIMON HU, ROTHENBERG ME, BOCHNER BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 45-49.
11. BAIN BJ, GILLILAND DG, HORNY HP, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008, p. 68-73.
12. VALENT P, KLION AD, HORNY HP, ROUFOSSE F, GOTLIB J, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607-612.
13. CHUSID MJ, DALE DC, WEST BC, WOLF SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 1975; 54: 1-27.
14. KLION AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology 2005; 209-14.
15. VAGLIO A, BUZIO C, ZWERINA J. Eosinophilic granulomatosis with polyangiitis (Churg – Strauss): state of the art. Allergy 2013; 68: 261-73.
16. LEFEBVRE C, BLETRY O, DEGOULET P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989; 140:253-7.
17. PODJASEK JC, BUTTERFIELD JH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res 2013; 37:392-5.
18. KLION AD. How I treat hypereosinophilic syndromes. Blood 2009;114(18): 3736-41.